Briacell Therap (BCTX) Competitors

Briacell Therap (NASDAQ:BCTX) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

Does the media favor BCTX or RLMD?

In the previous week, Briacell Therap had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 7 mentions for Briacell Therap and 5 mentions for Relmada Therapeutics. Briacell Therap's average media sentiment score of 0.26 beat Relmada Therapeutics' score of -0.05 indicating that Briacell Therap is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Briacell Therap	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts prefer BCTX or RLMD?

Briacell Therap presently has a consensus price target of $32.00, indicating a potential upside of 4,230.18%. Relmada Therapeutics has a consensus price target of $5.00, indicating a potential upside of 723.45%. Given Briacell Therap's stronger consensus rating and higher probable upside, analysts plainly believe Briacell Therap is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Relmada Therapeutics	0 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.25

Which has stronger earnings & valuation, BCTX or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Briacell Therap, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$4.79M	-$8.32	-0.09
Relmada Therapeutics	N/A	N/A	-$79.98M	-$2.22	-0.27

Is BCTX or RLMD more profitable?

Relmada Therapeutics' return on equity of -223.17% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-479.97%	-182.26%
Relmada Therapeutics	N/A	-223.17%	-180.41%

Which has more volatility & risk, BCTX or RLMD?

Briacell Therap has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.

Do institutionals & insiders believe in BCTX or RLMD?

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 5.7% of Briacell Therap shares are held by insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Briacell Therap beats Relmada Therapeutics on 7 of the 12 factors compared between the two stocks.